Who We Are

‍ ‍

The Founding Team:

The team combines deep expertise in causal AI, scientific machine learning, and drug target biology. We've built production AI systems at companies from early-stage to public listing, and we've done target discovery and validation inside pharma.

Sina Salek, PhD | CEO

Sina leads the development of TargetOS. His background is in theoretical physics and machine learning, with research at Oxford and Hong Kong University. In industry, he led causal inference at Babylon Health and built hybrid mechanistic-neural models for cell therapy manufacturing at Ori Biotech. At Geodesic Labs, he designed TargetOS's causal AI core, the engine that tells which genes are actually driving disease rather than just correlating with it.

Chantelle Hudson, PhD | CSO

Chantelle is a target discovery biologist who spent over seven years at BenevolentAI leading target identification and validation across twelve disease areas, delivering five validated targets into drug discovery portfolios in collaboration with partners including AstraZeneca. She has published peer-reviewed work validating AI-derived targets. At Geodesic Labs, she leads biological strategy: indication selection, target validation, and pressure-testing every nomination against the realities of the bench.

Chris Lucas, PhD | Tech Advisor

Chris is an experimental physicist with a background at CERN and the University of Bristol. Over the past decade he has built production ML systems across healthcare, insurance, and climate science, including research leadership at Babylon Health and Tractable. He currently leads the Machine Learning group at Fathom, working at the intersection of climate modelling and geospatial intelligence. At Geodesic Labs, Chris advises on technical architecture and model validation.

We’re being advised by:

A man with short salt and pepper hair and light blue eyes, wearing glasses and a blue and red plaid shirt, smiles at the camera against a plain white background.

Bryn Williams-Jones | Strategic Advisor

Bryn has over 30 years in drug discovery, spanning bench biochemistry, bioinformatics and AI. He spent nearly 20 years at Pfizer before leading a €20 million pre-competitive industry initiative spanning pharma, biotech and academia. From 2016 to 2023, he was SVP Drug Discovery at BenevolentAI, building its drug discovery function from its early days. He is now Founder and COO of Connected Discovery Ltd, advising pharma, biotech and CRO organisations on applying AI to drug programmes.